ACAD - ACADIA Pharmaceuticals Inc.
The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 21,126.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,498 shares of the biopharmaceutical company's stock after buying an additional 149,789 shares during the period. Bessemer Group
ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.
Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 44.9% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 954,855 shares of the biopharmaceutical company's stock after buying an additional 296,042 shares during the quarter. Allspring Global Investments Holdings
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions a.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conference ca.
Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximately ~$298,000 on June 26, 2026. The sale represented 46.60% of Kihara's direct holdings and reduced direct ownership to 13,088 shares.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. “Carl is a proven global leader with a stro.
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) regarding its drug DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in the European Union.
Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.
Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval of the Rett syndrome drug, Daybu.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company's clinical rationale for remlifanserin in Alzheimer's disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business development priorities.
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.